Overexpression of HOXD-AS2 is indicative of an unfavorable prognosis in glioma patients, and its upregulation promotes resistance to temozolomide, enhances MGMT expression, and reinforces the invasiveness of glioblastoma cells 36, 37. This evidence concerns the gene MGMT and glioma.